OBJECTIVE: We investigated whether, and the extent to which, vascular and degenerative lesions in the brain mediate the association of diabetes with poor cognitive performance. METHODS: This cross-sectional study included 4,206 participants (age > 65 years; 57.8% women) of the Age, Gene/Environment Susceptibility-Reykjavik Study. Data were collected through interview, clinical examination, psychological testing, and laboratory tests. The composite scores on memory, information-processing speed, and executive function were derived from a cognitive test battery. Markers of cerebral macrovascular (cortical infarcts), microvascular (subcortical infarcts, cerebral microbleeds, and higher white matter lesion volume), and neurodegenerative (lower gray matter, normal white matter, and total brain tissue volumes) processes were assessed on magnetic resonance images. Mediation models were employed to test the mediating effect of brain lesions on the association of diabetes with cognitive performance controlling for potential confounders. RESULTS: There were 462 (11.0%) persons with diabetes. Diabetes was significantly associated with lower scores on processing speed and executive function, but not with memory function. Diabetes was significantly associated with all markers of brain pathology. All of these markers were significantly associated with lower scores on memory, processing speed, and executive function. Formal mediation tests suggested that markers of cerebrovascular and degenerative pathology significantly mediated the associations of diabetes with processing speed and executive function. INTERPRETATION: Diabetes is associated with poor performance on cognitive tests of information-processing speed and executive function. The association is largely mediated by markers of both neurodegeneration and cerebrovascular disease. Older people with diabetes should be monitored for cognitive problems and brain lesions.
OBJECTIVE: We investigated whether, and the extent to which, vascular and degenerative lesions in the brain mediate the association of diabetes with poor cognitive performance. METHODS: This cross-sectional study included 4,206 participants (age > 65 years; 57.8% women) of the Age, Gene/Environment Susceptibility-Reykjavik Study. Data were collected through interview, clinical examination, psychological testing, and laboratory tests. The composite scores on memory, information-processing speed, and executive function were derived from a cognitive test battery. Markers of cerebral macrovascular (cortical infarcts), microvascular (subcortical infarcts, cerebral microbleeds, and higher white matter lesion volume), and neurodegenerative (lower gray matter, normal white matter, and total brain tissue volumes) processes were assessed on magnetic resonance images. Mediation models were employed to test the mediating effect of brain lesions on the association of diabetes with cognitive performance controlling for potential confounders. RESULTS: There were 462 (11.0%) persons with diabetes. Diabetes was significantly associated with lower scores on processing speed and executive function, but not with memory function. Diabetes was significantly associated with all markers of brain pathology. All of these markers were significantly associated with lower scores on memory, processing speed, and executive function. Formal mediation tests suggested that markers of cerebrovascular and degenerative pathology significantly mediated the associations of diabetes with processing speed and executive function. INTERPRETATION:Diabetes is associated with poor performance on cognitive tests of information-processing speed and executive function. The association is largely mediated by markers of both neurodegeneration and cerebrovascular disease. Older people with diabetes should be monitored for cognitive problems and brain lesions.
Authors: T den Heijer; S E Vermeer; E J van Dijk; N D Prins; P J Koudstaal; A Hofman; M M B Breteler Journal: Diabetologia Date: 2003-11-01 Impact factor: 10.122
Authors: Deniz Erten-Lyons; Hiroko H Dodge; Randall Woltjer; Lisa C Silbert; Diane B Howieson; Patricia Kramer; Jeffrey A Kaye Journal: JAMA Neurol Date: 2013-05 Impact factor: 18.302
Authors: Rosebud O Roberts; David S Knopman; Yonas E Geda; Ruth H Cha; V Shane Pankratz; Luke Baertlein; Bradley F Boeve; Eric G Tangalos; Robert J Ivnik; Michelle M Mielke; Ronald C Petersen Journal: Alzheimers Dement Date: 2013-04-03 Impact factor: 21.566
Authors: Jane S Saczynski; Sigurdur Siggurdsson; Palmi V Jonsson; Gudny Eiriksdottir; Elin Olafsdottir; Olafur Kjartansson; Tamara B Harris; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer Journal: Diabetes Care Date: 2009-06-09 Impact factor: 19.112
Authors: Fang-Chi Hsu; Laura M Raffield; Christina E Hugenschmidt; Amanda Cox; Jianzhao Xu; J Jeffery Carr; Barry I Freedman; Joseph A Maldjian; Jeff D Williamson; Donald W Bowden Journal: Neuroepidemiology Date: 2015-07-14 Impact factor: 3.282
Authors: Dimitrios Kapogiannis; Adam Boxer; Janice B Schwartz; Erin L Abner; Arya Biragyn; Umesh Masharani; Lynda Frassetto; Ronald C Petersen; Bruce L Miller; Edward J Goetzl Journal: FASEB J Date: 2014-10-23 Impact factor: 5.191